Peptide reference
Dulaglutide
Trulicity ·LY2189265
What cited sources report about dulaglutide
Dulaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly and marketed as Trulicity. Unlike acylated peptides such as semaglutide and liraglutide, dulaglutide is a recombinant fusion protein in which two modified GLP-1 analog peptides are covalently linked to an Fc fragment of human immunoglobulin G4. The resulting ~63 kDa molecule has a half-life of approximately five days, supporting once-weekly subcutaneous dosing. Dulaglutide is FDA-approved, EMA-authorised, and approved in Canada, Australia, and Japan; it has not been nominated to the FDA Pharmacy Compounding Advisory Committee. The summaries below report what individual cited sources state.
FDA Drug Label — Trulicity (revised March 12, 2026)
The DailyMed structured product label for Trulicity (Eli Lilly) lists two approved indications: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and either established cardiovascular disease or multiple cardiovascular risk factors. The label describes glucose-dependent insulin secretion, suppression of glucagon, and slowed gastric emptying.
As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
Scott (2020) — Drugs
A 2020 review in the Adis journal Drugs surveyed the AWARD phase III program for dulaglutide in adults with inadequately controlled type 2 diabetes and the REWIND cardiovascular outcomes trial. The author reported sustained glycemic control with dulaglutide as monotherapy and as add-on therapy, weight reduction, a low risk of hypoglycemia outside insulin combinations, and a reduction in major adverse cardiovascular events in REWIND. Tolerability was characterized as broadly consistent with the GLP-1 receptor agonist class.
Subcutaneous dulaglutide (Trulicity) is a once-weekly glucagon-like peptide-1 receptor agonist
DrugBank DB09045 — Dulaglutide
The DrugBank record for dulaglutide describes the molecule as a recombinant fusion of two modified GLP-1 analog peptides covalently linked to an Fc fragment of human immunoglobulin G4. The Fc fragment raises molecular weight to approximately 63 kDa and slows renal clearance, supporting a half-life of around five days and a once-weekly dosing interval. Modifications to the GLP-1 sequence reduce susceptibility to dipeptidyl peptidase-4 (DPP-4) cleavage.
Coverage notes
The pivotal evidence base for dulaglutide is the AWARD program (head-to-head comparators including metformin, sitagliptin, exenatide, insulin glargine, and liraglutide) and the REWIND cardiovascular outcomes trial. REWIND was notable for enrolling a population in which approximately 70% of participants had cardiovascular risk factors but no established cardiovascular disease, supporting the broader cardiovascular labelling reflected in the current Trulicity label.